logo-loader
viewCircassia Pharmaceuticals PLC

Block Listing Application

/**/ .f{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.f{}p.q{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.o{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.r{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.m{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif"}p.s{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.k{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.t{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-decoration: underline}span.i{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black} p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.g{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black} /**/
RNS Number : 3997D
Circassia Pharmaceuticals Plc
25 June 2019
 

25 June 2019

Circassia Pharmaceuticals plc

Block Listing Application

Circassia Pharmaceuticals plc ("Circassia" or "the Company") today announces that an application (the "Application") has been made to the London Stock Exchange for a block listing of 930,000 ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

The Application relates to Ordinary Shares to be issued from time to time in order to satisfy the potential exercise of share options granted under the 2016 Performance Share Plan Scheme.

It is expected that admission will become effective on 1 July 2019. When issued, the Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.

-Ends-

For further information, please contact:

Circassia Pharmaceuticals plc

Julien Cotta, Company Secretary                                                     Tel: +44 (0) 1865 405 560


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSBUGDLLUDBGCU

Quick facts: Circassia Pharmaceuticals PLC

Price: 17.2

Market: LSE
Market Cap: £64.53 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19